How is nafarelin taken?

It is a metered nasal spray used once or twice daily, with dose and duration set by the treating physician for the specific condition.

Does nafarelin cause an initial flare?

Yes. As a GnRH agonist it first stimulates the pituitary, transiently raising sex hormones before it suppresses them.

What are the common side effects?

Hot flushes, vaginal dryness, headache and other low-estrogen effects in adults, plus loss of bone density with prolonged use.

How does nafarelin differ from leuprolide or buserelin?

All are GnRH agonists with the same flare-then-suppression mechanism; nafarelin's distinguishing feature is intranasal delivery rather than injection or implant.

EMA-approvedaka Synarel

Nafarelin — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Nafarelin (also known as Synarel) is a peptide catalogued under Sexual Health (GnRH agonist). It is described as: GnRH receptor agonist. Documented context: Endometriosis; precocious puberty. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Nafarelin?

Nafarelin (brand name Synarel) is an intranasal GnRH-agonist analog.

It is FDA-approved and marketed for endometriosis and for central (gonadotropin-dependent) precocious puberty.

The evidence base is strong and human, including multiple randomized controlled trials versus danazol and a comparative pediatric literature in precocious puberty.

How does Nafarelin work?

Like other GnRH agonists, nafarelin first stimulates the pituitary and causes a transient flare in LH, FSH and sex steroids.

Continued twice-daily intranasal dosing then desensitizes and downregulates pituitary GnRH receptors, suppressing gonadotropins and estrogen (or, in children, the premature sex-steroid drive).

What does the research say about Nafarelin?

Nafarelin relieves endometriosis pain and reduces implants with efficacy comparable to danazol in randomized trials. ^[2]
Nafarelin is effective and generally well tolerated for endometriosis, with hypoestrogenic rather than androgenic side effects. ^[1]
In central precocious puberty, intranasal nafarelin suppresses the premature gonadotropin-dependent activation of the axis. ^[6]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Efficacy and safety of nafarelin in the treatment of endometriosis — Henzl MR et al., American Journal of Obstetrics and Gynecology 1990. (Clinical trial report)
[2] A comparison of nafarelin acetate and danazol in the treatment of endometriosis — Kennedy SH et al., Fertility and Sterility 1990. (Randomized comparative trial)
[3] Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions — Chrisp P et al., Drugs 1990. (Narrative pharmacology review)
[4] A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone — Bergqvist A et al., Gynecological Endocrinology 1997. (Double-blind randomized controlled trial)
[5] A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan — Cheng MH et al., Journal of the Chinese Medical Association 2005. (Randomized controlled trial)
[6] Intranasal nafarelin: an LH-RH analogue treatment of gonadotropin-dependent precocious puberty — Lin TH et al., Journal of Pediatrics 1986. (Clinical study)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Nafarelin is delivered as a metered intranasal spray, typically dosed once or twice daily with the schedule set by the treating physician for endometriosis or precocious puberty.

This is contextual information about how it is used clinically, not a self-administration protocol.

Side effects & safety profile

An initial agonist flare transiently raises sex-steroid levels before suppression is achieved.

Hypoestrogenic effects such as hot flushes, vaginal dryness and headache are the most common adverse effects in adults.

Prolonged use lowers bone mineral density, which limits treatment duration and prompts use of add-back therapy in endometriosis.

Stacking & combinations

In endometriosis it may be combined with estrogen/progestin add-back therapy under medical supervision to limit bone loss and vasomotor symptoms during extended treatment.

Finding Nafarelin vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

In the US it is FDA-approved as an intranasal spray (Synarel) for endometriosis and for central (gonadotropin-dependent) precocious puberty.

References

[1] Efficacy and safety of nafarelin in the treatment of endometriosis — Henzl MR et al., American Journal of Obstetrics and Gynecology 1990. PMID: 2137971. View sourceStudy: Clinical trial reportNafarelin effectively reduced endometriosis symptoms and lesions with a hypoestrogenic safety profile.
[2] A comparison of nafarelin acetate and danazol in the treatment of endometriosis — Kennedy SH et al., Fertility and Sterility 1990. PMID: 2140996. View sourceStudy: Randomized comparative trialNafarelin and danazol produced similar improvement in endometriosis, with differing side-effect profiles.
[3] Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions — Chrisp P et al., Drugs 1990. PMID: 2140979. View sourceStudy: Narrative pharmacology reviewReviews nafarelin's GnRH-agonist pharmacology and clinical role in endometriosis and other sex-hormone-related conditions.
[4] A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone — Bergqvist A et al., Gynecological Endocrinology 1997. PMID: 9209899. View sourceStudy: Double-blind randomized controlled trialAdding norethisterone add-back to nafarelin maintained efficacy while reducing hypoestrogenic side effects.
[5] A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan — Cheng MH et al., Journal of the Chinese Medical Association 2005. PMID: 16038370. View sourceStudy: Randomized controlled trialNafarelin was comparable to danazol for endometriosis with a more favorable tolerability profile.
[6] Intranasal nafarelin: an LH-RH analogue treatment of gonadotropin-dependent precocious puberty — Lin TH et al., Journal of Pediatrics 1986. PMID: 2946840. View sourceStudy: Clinical studyIntranasal nafarelin suppressed gonadotropins and sex steroids in children with central precocious puberty.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.